Axsome Therapeutics's Q2 revenue rises 72% to $150 mln

Axsome Therapeutics

04/08/2025 12:12

Overview

Axsome Q2 2025 net product revenue grows 72% yr/yr to $150 mln

AUVELITY sales increase 84% yr/yr, driving revenue growth

Net loss narrows to $48 mln from $79.3 mln in prior year

Outlook

Axsome plans AXS-05 sNDA submission for Alzheimer's agitation in 3Q 2025

Company expects AXS-12 NDA submission for narcolepsy in 4Q 2025

Axsome to initiate Phase 3 trials for solriamfetol in ADHD, MDD in 4Q 2025

Company confident current cash will fund operations to cash flow positivity

Result Drivers

AUVELITY SALES - AUVELITY sales grew 84% yr/yr to $119.6 mln, driven by expanded market access with 28 mln new covered lives

SUNOSI GROWTH - SUNOSI sales increased 35% yr/yr to $30 mln, supported by strong prescription growth

SYMBRAVO LAUNCH - SYMBRAVO launched in June, contributing $0.4 mln to Q2 revenue

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 EPS
-$0.97
Q2 Net Income
-$47.97 mln
Q2 Operating Expenses
$186.76 mln
Q2 Operating Income
-$36.71 mln
Q2 Pretax Profit
-$48.93 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 19 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Axsome Therapeutics Inc is $181.50, about 43.2% above its August 1 closing price of $103.02

Press Release: ID:nGNX53blZ6

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)